TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Earnings for TScan Therapeutics, Inc. (TCRX)
Earnings in 2023 (TTM): $-89,218,000
According to TScan Therapeutics, Inc.'s latest financial reports the company's current earnings (TTM) are $-89,218,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of TScan Therapeutics, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-89,218,000 | $-89,218,000 |
| 2022 | $-66,221,000 | $-65,806,000 |
| 2021 | $-48,625,000 | $-48,625,000 |
| 2020 | $-26,127,000 | $-26,021,000 |
| 2019 | $-13,658,000 | $-13,106,000 |